EP Patent

EP0850926A2 — Difluoroprostaglandin derivatives and their use

Assigned to Santen Pharmaceutical Co Ltd · Expires 1998-07-01 · 28y expired

What this patent protects

A fluorine-containing prostaglandin derivative of the formula (1) or a salt thereof, and a medicine containing it, particularly, as a preventive or therapeutic medicine for an eye disease: wherein A is a vinylene group or the like, R 1 is an aryloxyalkyl group or the like, R 2…

USPTO Abstract

A fluorine-containing prostaglandin derivative of the formula (1) or a salt thereof, and a medicine containing it, particularly, as a preventive or therapeutic medicine for an eye disease: wherein A is a vinylene group or the like, R 1 is an aryloxyalkyl group or the like, R 2 and R 3 are hydrogen atoms or the like, and Z is OR 4 , therein OR 4 is a hydrogen atom or an alkyl group or the like.

Drugs covered by this patent

Patent Metadata

Patent number
EP0850926A2
Jurisdiction
EP
Classification
Expires
1998-07-01
Drug substance claim
No
Drug product claim
No
Assignee
Santen Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.